Study to compare the efficacy of alemtuzumab with other MS disease modifying therapies (DMTs) in relapsing-remitting MS (RRMS).

Trial Profile

Study to compare the efficacy of alemtuzumab with other MS disease modifying therapies (DMTs) in relapsing-remitting MS (RRMS).

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2017 New trial record
    • 28 Oct 2017 Results assessing efficacy of alemtuzumab with other MS disease modifying therapies (DMTs) in relapsing-remitting MS (RRMS), were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top